X

Trial Profile

A Phase I, Open Label Trial to Evaluate the Safety and Immunogenicity of AERAS-402 Followed by MVA85A in BCG Vaccinated Adults (TB032)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Oct 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MVA 85A (Primary) ; Tuberculosis vaccine (Primary)
Indications Tuberculosis
Focus Adverse reactions

Most Recent Events

07 Oct 2014 Accrual to date is 134% according to United Kingdom Clinical Research Network
16 Sep 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
10 Apr 2014 Accrual to date is 102% according to United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com